Introduction
============

Antidepressants are effective treatments for major depressive disorder (MDD). Selective serotonin reuptake inhibitors (SSRIs) are widely used to treat patients with MDD, and evidence suggests that several SSRIs are good first-line drugs for treating a current depressive episode.[@b1-ndt-11-3031],[@b2-ndt-11-3031] However, only approximately 30% of patients with MDD treated with the typical SSRI citalopram achieved symptomatic remission with the initial pharmacological treatment.[@b3-ndt-11-3031] Thus, it is extremely important to investigate alternative treatment strategies, such as switching to another antidepressant, for MDD patients for whom initial SSRI treatment failed.

Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) that is used for the treatment of MDD in a number of countries. As the name suggests, milnacipran inhibits both serotonin and norepinephrine reuptake through high-affinity transporter binding, with potencies for both serotonin and norepinephrine equivalent to other SNRIs such as venlafaxine and duloxetine.[@b4-ndt-11-3031]--[@b6-ndt-11-3031] Results of a previous meta-analysis suggest that switching to another class of antidepressants (eg, SNRIs) is better than switching to other SSRIs in the treatment of patients with SSRI-resistant MDD.[@b7-ndt-11-3031] Milnacipran's pharmacological profile is different from other SNRIs with regard to its binding affinities, potencies of reuptake inhibition, and transporter selectivity. Specifically, milnacipran has a higher selectivity for the norepinephrine transporter compared to venlafaxine and duloxetine.[@b4-ndt-11-3031],[@b8-ndt-11-3031] There are few studies about the effects of switching patients with MDD to more noradrenergic-selective antidepressants following an initial SSRI treatment failure, in terms of not only clinical outcomes of efficacy and safety, but also the exploration of potential biomarkers that could indicate SSRI resistance, SNRI effectiveness, or the likelihood of adverse effects (AEs).

One method for identifying putative biomarkers related to treatments for MDD is to measure blood levels of molecules related to inflammation or neuronal function. We therefore measured the levels of various molecular species from peripheral blood samples, which included interleukin-6 (IL-6), interleukin-8 (IL-8), macrophage inflammatory protein (MIP)-1β, brain-derived neurotrophic factor (BDNF), serotonin, and the catecholamine metabolites homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and 3-methoxy-4-hydroxyphenylglycol (MHPG). These were chosen based on information from previous studies.[@b9-ndt-11-3031]--[@b14-ndt-11-3031]

The primary aim of this study was to assess the efficacy and safety of switching to milnacipran in patients with MDD following an initial SSRI treatment failure. The secondary aim of this study was to seek potential biomarkers by correlating clinical outcomes and blood levels of molecules that were presumably associated with MDD or its treatment.

Methods
=======

Participants
------------

Patients were recruited to the study at four sites in Japan. This study was conducted from April 2010 to March 2013. For inclusion criteria to be met, prospective subjects had to be 1) aged 20--74 years; 2) diagnosed according to the *DSM-IV-TR* criteria for MDD;[@b15-ndt-11-3031] 3) unremitted patients treated by an SSRI (paroxetine, fluvoxamine, sertraline, or escitalopram) for at least 6 weeks prior to this study, and 4) with the score of the 17-item Hamilton Depression Rating Scale (HDRS)[@b16-ndt-11-3031] at the baseline was 14 or more. For exclusion criteria to be met, potential subjects had to be one of the following: 1) treated with selegiline hydrochloride; 2) allergic to milnacipran; 3) suffering from urinary retention; 4) pregnant or breast-feeding; 5) at significant risk of suicide; 6) diagnosed with a primary diagnosis including dementia, bipolar disorder, obsessive--compulsive disorder, eating disorders, or schizophrenia or other psychotic disorders; and 7) dealing with medical conditions judged to make the patient improper for use as a trial subject.

Ethics
------

The trial was approved by the Institutional Review Board of Chiba University Hospital (Chiba, Japan), and performed in accordance with the ethical standards laid down in the Helsinki Declaration of 1975, as revised in 1983. The trial was registered on the Clinical Trials Registry of the University Hospital Medical Information Network (UMIN, Tokyo, Japan) under registration number UMIN000003516. All subjects provided written informed consent for their participation in the study after the procedure had been fully explained to them.

Study design and procedure
--------------------------

We conducted a multicentre, prospective, open-label, 24-week trial. The starting dose of milnacipran was 25 mg in the first 1--2 weeks. Titration of the milnacipran dosage was flexible, from 100 to 200 mg, on the basis of the clinical judgment of the treating psychiatrists. However, the option to decrease the dosage for intolerance remained available. A given participant's visit frequency was every 1--2 weeks in principle, to assess the safety of milnacipran, up to 8 weeks. Meanwhile, participants were tapered off their prior SSRIs for the first 4 weeks. The patients were evaluated at the baseline, and then after 4, 8, 12, and 24 weeks. Blood samples of the participants were collected from peripheral veins on the same day as the clinical evaluation.

Clinical assessments
--------------------

To assess the severity of depressive symptoms, we used the HDRS. Response to milnacipran was defined as a ≥50% reduction in the HDRS score from baseline to each assessment day. Remission was defined by an HDRS score ≤7. We classified patients as responders, non-responders, and remitters at each point of the study, such that responders and remitters satisfied their respective definitions described earlier, and those patients who satisfied neither the responder nor remitter definitions were classified as non-responders. We also assessed patients using the Montgomery--Asberg Depression Rating Scale (MADRS),[@b17-ndt-11-3031] the 16-item Quick Inventory of Depressive Symptomatology-Self-Report -- Japanese version (QIDS-SRJ),[@b18-ndt-11-3031],[@b19-ndt-11-3031] and the Clinical Global Impressions-Severity (CGI-S) scale.[@b20-ndt-11-3031] To assess social function, we used the Japanese version of the Social Adaptation Self-evaluation Scale (SASS-J),[@b21-ndt-11-3031] which is a validated self-evaluation scale for assessment of social functioning.[@b22-ndt-11-3031] The HDRS, MADRS, QIDS-SRJ, SASS, and CGI-S scores were measured at the baseline and 4, 8, 12, and 24 weeks.

In terms of safety, we collected information on all the AEs experienced by the participants during this study. We identified moderate-to-severe AEs as effects for which patients underwent medical treatments or were forced to withdraw from this study. We did not include moderate-to-severe AEs which patients experienced, but which required no intervention. We defined serious AEs as those causing death, any life-threatening conditions, hospitalization, or persistent disability.

Blood sample collection and measurements of molecules
-----------------------------------------------------

All blood samples were collected between 10 am and 12 pm, at least 3 hours after breakfast, and were done at the same approximate time for each participant at every visit, although we did not strictly set a diet restriction. Serum samples were rapidly delivered to the Department of Psychiatry, Chiba University Graduate School of Medicine in anticoagulant tubes at 4°C, and stored at −80°C until use. The serum levels of IL-6, IL-8, MIP-1β, and BDNF were measured using the respective specific enzyme-linked immunosorbent assay kit (R&D Systems, Minneapolis, MN, USA). Plasma 5-HIAA, HVA, and MHPG concentrations, as well as whole blood serotonin concentration, were measured by SRL Inc. (Tokyo, Japan) using their standard laboratory protocols, including evaluation via high-performance liquid chromatography. Reference values provided by SRL on the basis of data from more than 100 healthy people were whole blood levels of serotonin, 57--230 (ng/mL); plasma levels of 5-HIAA, 1.0--6.0 (ng/mL); HVA, 4.4--15.1 (ng/mL); and MHPG 3.2--5.9 (ng/mL) (SRL, <http://www.srl-group.co.jp/>). Platelet counts were conducted at the Department of Molecular Diagnosis of Chiba University Hospital.[@b23-ndt-11-3031] Since platelets store serotonin,[@b24-ndt-11-3031] we calculated platelet serotonin as whole blood serotonin corrected with division by platelet number, to make the adjustment to whole blood serotonin measurements in participants that would be comparable to previous studies.[@b13-ndt-11-3031],[@b25-ndt-11-3031]

Exploration of biomarkers from blood molecules on the basis of clinical outcomes
--------------------------------------------------------------------------------

We first identified the clinical outcomes for participants in this study. We defined the short-term effectiveness of switching to milnacipran as the effect at the 8-week assessment, according to the convention used in Phase III clinical trials.[@b26-ndt-11-3031] The long-term effectiveness was defined by the result of the 24-week (final) assessment. Once the clinical outcomes and their distinct features were determined, we examined the relationships between these data and the data on the assayed blood chemicals to identify potential biomarkers.

Statistical analyses
--------------------

We used parametric tests for the values of clinical measures because the data showed normal distribution. Data analyses were conducted on an intent-to-treat basis. Longitudinal efficacy outcomes (HDRS, MADRS, QIDS-SRJ, SASS-J, and CGI-S) were analyzed using a linear mixed effects model for repeated measures data with week as a fixed effect and subject as a random effect. Bonferroni's adjustment was used for multiple comparisons.

We used non-parametric tests for the values of biological data from blood samples which did not follow a normal distribution. To analyze the changes of molecule levels in blood samples in the same individuals, we conducted Friedman's test to screen for significance, followed by the Wilcoxon signed rank test. In comparisons between independent groups for biological values, we used the Mann--Whitney *U*-test. Two-tailed *P*-values below 0.05 were considered to indicate statistical significance in all analyses. All analyses were conducted using SPSS, version 20.0 (IBM Corporation, Armonk, NY, USA).

Results
=======

Participants and clinical course outline
----------------------------------------

We screened 48 outpatients with MDD after initial SSRI treatment failure, of which 30 were enrolled in this study. Their demographic data are presented in [Table 1](#t1-ndt-11-3031){ref-type="table"}.

By the first 8 weeks, ten participants withdrew due to AEs (n=8) or clinical deterioration (n=2) ([Figure 1](#f1-ndt-11-3031){ref-type="fig"}). Three more participants discontinued the study due to insufficient therapeutic response ([Figure 1](#f1-ndt-11-3031){ref-type="fig"}), so 17 participants ultimately completed this study ([Figure 1](#f1-ndt-11-3031){ref-type="fig"}). The daily mean peak dose of milnacipran was 108.8 mg (standard deviation \[SD\] 55.7), with a dose range of 12.5--200 mg. The average dose of milnacipran at the end of this study was 123.5 mg (SD 48.0).

Efficacy
--------

The clinical assessments at the baseline and each time point are presented in [Table 2](#t2-ndt-11-3031){ref-type="table"}. As shown in [Table 2](#t2-ndt-11-3031){ref-type="table"}, the HDRS scores were significantly reduced (ie, improved) vs baseline at 4, 8, 12, and 24 weeks. The other measurements to assess severity of depression, including the MADRS and the QIDS-SRJ also significantly decreased at each time point compared to baseline. The CGI-S and SASS-J scores increased (ie, improved) significantly at 8, 12, and 24 weeks, but not at 4 weeks, from baseline.

Safety
------

The details of AEs in this study are shown in [Table 3](#t3-ndt-11-3031){ref-type="table"}. A total of 23 AEs were reported by 16 patients over the study period. All AEs were considered to be related to milnacipran treatment and occurred within the first 4 weeks. No late-onset AEs (after the first 4 weeks) occurred. [Table 3](#t3-ndt-11-3031){ref-type="table"} provides the number and details of moderate-to-severe AEs. The rate of patients with moderate-to-severe AEs was 43.3% (n=13) in all 30 participants ([Table 3](#t3-ndt-11-3031){ref-type="table"}). No serious AEs were observed in this study. Eight patients withdrew from this study because of AEs within 8 weeks, but no further withdrawals occurred ([Figure 1](#f1-ndt-11-3031){ref-type="fig"}).

The relationships between clinical outcomes and possible blood biomarkers
-------------------------------------------------------------------------

As noted in [Table 4](#t4-ndt-11-3031){ref-type="table"}, baseline serum levels of IL-6 and IL-8 were significantly higher in patients with moderate-to-severe AEs than in those patients without them. The levels of whole blood serotonin and platelet serotonin in patients with moderate-to-severe AEs were also significantly higher than in those patients without moderate-to-severe AEs ([Table 4](#t4-ndt-11-3031){ref-type="table"}).

Serum MIP-1β levels were assessed in the 17 participants who completed the full 24 weeks of the study, and were found to be significantly decreased from baseline (Friedman's test, *χ*^2^=18.8, *df*=4, *P*\<0.001). Moreover, comparing milnacipran responders to non-responders, serum levels of MIP-1β in non-responders (n=8) significantly decreased from baseline at all time points tested (Friedman's test: *χ*^2^=23.9, *df*=4, *P*\<0.001; the Wilcoxon signed rank test: at 4, 8, and 12 weeks, *Z*=−2.5, *P*\<0.05; at 24 weeks, *Z*=−2.1, *P*\<0.05, respectively), while those in responders (n=9) were not decreased at any time points ([Figure 2](#f2-ndt-11-3031){ref-type="fig"}). As shown in [Figure 3](#f3-ndt-11-3031){ref-type="fig"}, whole blood serotonin levels significantly increased above baseline over time in both responders (n=9) (Friedman's test: *χ*^2^=21.8, *df*=4, *P*\<0.001; the Wilcoxon signed rank test: at 4 weeks, *Z*=−2.3, *P*\<0.05; at 8 weeks, *Z*=−2.5, *P*\<0.05; at 12 and 24 weeks, *Z*=−2.7, *P*\<0.01) and non-responders (n=8) (Friedman's test: *χ*^2^=16.5, *df*=4, *P*\<0.01; the Wilcoxon signed rank test: at 8, 12, and 24 weeks, *Z*=−2.4, *P*\<0.05) ([Figure 3](#f3-ndt-11-3031){ref-type="fig"}). Platelet serotonin levels also significantly increased from baseline in both groups, responders (n=9) (Friedman's test: *χ*^2^=21.8, *df*=4, *P*\<0.001; the Wilcoxon signed rank test: at 4 weeks, *Z*=−2.2, *P*\<0.05; at 8 weeks, *Z*=−2.5, *P*\<0.05; at 12 and 24 weeks, *Z*=−2.7, *P*\<0.01) and non-responders (n=8) (Friedman's test: *χ*^2^=16.5, *df*=4, *P*\<0.01; the Wilcoxon signed rank test: at 8, 12, and 24 weeks, *Z*=−2.4, *P*\<0.05), while the levels of the other molecules were not statistically different (data not shown).

Discussion
==========

Five important results from this study deserve further mention here. First, in terms of efficacy, switching to milnacipran following an initial SSRI failure resulted in a 30.0% response rate, and a 23.3% remission rate, at the final assessment of patients with MDD. Second, in terms of safety, all AEs occurred in the early period (up to 4 weeks) after administration of milnacipran began, and the moderate-to-severe AEs were the main reason for withdrawal from this study. Third, this study showed that when moderate-to-severe AEs occurred after switching to milnacipran, the baseline serum levels of IL-6 and IL-8 in patients with them were significantly higher than in patients without them. Fourth, serum levels of MIP-1β decreased, and remained decreased throughout the 24-week trial period, in patients with MDD who did not respond to milnacipran. Fifth, whole blood levels of serotonin and platelet serotonin in patients, regardless of responsiveness condition, were increased after switching to milnacipran, and remained increased over the full study duration.

Switching to milnacipran following an initial SSRI failure resulted in a 30.0% response rate, and a 23.3% remission rate, at the final assessment of patients with MDD in this study. Other studies have examined the efficacy of switching pharmacotherapies following SSRI failure. In a representative large sample study, the Sequenced Treatment Alternatives to Relieve Depression (STAR\*D) trial,[@b27-ndt-11-3031] switching to other pharmacotherapies or cognitive therapy as the next step in patients with depression whose initial citalopram (SSRI) treatment failed produced a 27.3% rate of response and a 27.0% rate of remission. Moreover, a recent study reported that the efficacy of switching to the SNRI venlafaxine in patients whose first antidepressant Our results herein are largely consistent with these studies, suggesting that switching to milnacipran could be an optional strategy for patients with MDD following failure of treatment with an SSRI or other type of antidepressant. Clearly, though, identifying predictors of treatment responsiveness in the pharmacotherapy of major depression would be a boon to clinical practice.

All AEs occurred in the first 4 weeks after administration of milnacipran had begun. Most AEs in this study were considered specific symptoms of inhibiting neuronal nor-epinephrine reuptake[@b29-ndt-11-3031] as SNRIs do by definition. Although previous reports described SNRIs such as milnacipran as comparatively well tolerated,[@b29-ndt-11-3031]--[@b31-ndt-11-3031] minimizing side effects is important, especially for patients with depression who may have already experienced failure of their initial antidepressant treatments. Establishing means to prevent or prepare for the side effects related to switching pharmacotherapies is needed in clinical practice.

To the best of our knowledge, this is the first study to demonstrate that higher serum levels of IL-6 and IL-8 at the baseline could be related to adverse clinical effects of an antidepressant treatment in patients with major depression. However, several previous studies have described relationships between blood levels of cytokines or serotonin at the baseline and therapeutic responses in depressed patients.[@b32-ndt-11-3031]--[@b35-ndt-11-3031] An inflammatory mechanism is thought to play an important role in the pathophysiology of depression.[@b36-ndt-11-3031]--[@b38-ndt-11-3031] Hyperactivity of the sympathetic nervous system is associated with inflammatory dysregulation in patients with depression.[@b38-ndt-11-3031] Moreover, norepinephrine reuptake inhibitors such as milnacipran enhance noradrenergic action in the synaptic clefts.[@b39-ndt-11-3031] Therefore, it seems reasonable that patients with greater inflammation, as reflected by higher serum levels of IL-6 and IL-8, may be more likely to suffer from adverse side effects due to administration of noradrenergic antidepressants such as milnacipran. Measurements of serum IL-6 and IL-8 levels before administration of noradrenergic antidepressants might therefore be useful as predictive biomarkers to guide the direction of further treatment.

This study is also the first to report that serum levels of MIP-1β are continuously decreased in non-responsive, but not in responsive, patients with depression after administration of a noradrenergic antidepressant. MIP-1β is a chemokine, or chemotactic cytokine, which is related to the movement of leukocytes to sites of inflammation in injury or inflammatory diseases.[@b40-ndt-11-3031] Two in vitro studies have demonstrated that norepinephrine modulates the release of some cytokines from dendritic cells.[@b41-ndt-11-3031],[@b42-ndt-11-3031] Although the mechanism behind the decrease in serum MIP-1β here is still unknown, switching to milnacipran might directly affect serum MIP-1β through its noradrenergic activity. With regard to clinical practice, Lehto et al reported lower serum levels of MIP-1β in patients with depression than in healthy people, a result they ascribed to prolonged depressive symptoms.[@b12-ndt-11-3031] Given that our non-responders would have residual and persistent depressive symptoms, our results are compatible with those of the above report. Thus, a change in serum MIP-1β levels may represent a monitorable biomarker for responsiveness to treatment with noradrenergic antidepressants such as milnacipran.

Serotonin levels were also significantly different following the switch to milnacipran, regardless of responsiveness. Serotonin in the blood is mainly stored in platelets, which acquire the serotonin through cell-surface serotonin transporters.[@b24-ndt-11-3031] SSRIs and related antidepressants such as tricyclics inhibit serotonin reuptake, and can decrease blood serotonin levels by blocking platelet-mediated storage.[@b32-ndt-11-3031],[@b43-ndt-11-3031]--[@b46-ndt-11-3031] Because milnacipran has lower potency and binding affinity for the serotonin transporter compared to SSRIs,[@b4-ndt-11-3031],[@b8-ndt-11-3031] it would also increase blood serotonin levels relative to an SSRI, as both our data and the abovementioned studies confirmed. It is possible for SSRIs to predispose patients to a risk of bleeding through the suppression of platelet function.[@b47-ndt-11-3031],[@b48-ndt-11-3031]

Moreover, in comparison to other SNRIs, given that the selectivity for the serotonin transporter is relatively higher compared to other SNRIs such as venlafaxine and duloxetine than milnacipran,[@b4-ndt-11-3031],[@b8-ndt-11-3031] milnacipran might not affect bleeding risk better than other SNRIs. Our findings here indicate that milnacipran might be a suitable antidepressant for the treatment of patients with depression who may also be at risk for bleeding problems.

In addition, the data herein also demonstrated that the baseline whole blood levels of serotonin were different between patients with and without moderate-to-severe AEs after switching to milnacipran treatment. However, this result is difficult to interpret, because both the baseline levels in patients with and without moderate-to-severe AEs were remarkably lower than the reference values of whole blood serotonin related to prior SSRI treatments.[@b32-ndt-11-3031],[@b43-ndt-11-3031]--[@b46-ndt-11-3031] To clarify this relationship in milnacipran treatment, studies excluding patients treated with serotonin reuptake inhibitor-based antidepressants will need to be designed.

Three main limitations to this study must be noted. First, this study was not rigorously designed. To confirm our findings, especially those regarding efficacy and safety in switching to milnacipran treatment, a rigorous study including control groups (placebo and/or other antidepressants), randomized assignments, and double-blind assessments must be performed. Second, the sample size of this study was small. Further studies with a larger sample are needed to establish not only the clinical effects, but also to verify the current potential biomarkers and identify new ones. Third, the relationships between our putative biomarkers (IL-6, IL-8, and MIP-1β) and the clinical outcomes are thus far limited to those related to switching to an SNRI in patients with depression who were treated with an SSRI first. Whether these biomarkers can be generalized to other SNRIs or other treatment regimens remains to be seen. Indeed, the utility of these biomarkers is a key question requiring further studies, such as those including other noradrenergic antidepressants and/or a patient cohort with no prior SSRI exposure.

Conclusion
==========

This study showed that switching to milnacipran is a potentially effective strategy in the pharmacological treatment of patients with depression following the failure to respond to an initial SSRI. Moreover, our study identified serum levels of IL-6, IL-8, and MIP-1β as potential blood biomarkers that could be utilized to identify the responsiveness of patients to SNRIs such as milnacipran, or to identify those patients who may experience AEs strong enough to warrant discontinuation of treatment.
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![Patient flowchart and reasons for withdrawal during this study.](ndt-11-3031Fig1){#f1-ndt-11-3031}

![Changes in serum levels of macrophage inflammatory protein-1β (MIP-1β).\
**Note:** \**P*\<0.05 vs baseline, Friedman's test followed by the Wilcoxon signed rank test.](ndt-11-3031Fig2){#f2-ndt-11-3031}

![Changes in whole blood levels of serotonin.\
**Notes:** \**P*\<0.05 vs baseline, Friedman's test followed by the Wilcoxon signed rank test. \*\**P*\<0.01 vs baseline, Friedman's test followed by the Wilcoxon signed rank test. ^\#^*P*\<0.05 vs baseline, Friedman's test followed by the Wilcoxon signed rank test.](ndt-11-3031Fig3){#f3-ndt-11-3031}

###### 

Patient characteristics at baseline

  Characteristics                                    Value
  -------------------------------------------------- -------------
  Age, mean (SD), years                              51.3 (13.6)
  Sex, male/female, n                                16/14
  Age at depression onset, mean (SD), years          45.6 (15.1)
  Major depressive episodes                          
   Single episode, n                                 12
   Recurrent, n                                      18
  Duration of prior SSRI therapy, mean (SD), weeks   83 (110)
   Range, weeks                                      6--350
  Prior SSRI                                         
   Paroxetine, n                                     12
   Sertraline, n                                     15
   Fluvoxamine, n                                    3
  HDRS, mean (SD)                                    19.2 (0.8)
   Range                                             14--28
  MADRS, mean (SD)                                   24.7 (6.5)
   Range                                             15--36
  QIDS-SRJ, mean (SD)                                12.5 (4.6)
   Range                                             7--24
  CGI-S, mean (SD)                                   4.2 (0.7)
   Range                                             3--6
  SASS-J, mean (SD)                                  25.9 (7.3)
   Range                                             11--34

**Abbreviations:** SSRI, selective serotonin reuptake inhibitor; SD, standard deviation; HDRS, 17-item Hamilton Depression Rating Scale; MADRS, Montgomery-Asberg Depression Rating Scale; QIDS-SRJ, 16-item Quick Inventory of Depressive Symptomatology-Self-Report -- Japanese version; CGI-S, Clinical Global Impressions-Severity; SASS-J, Social Adaptation Self-evaluation Scale.

###### 

Baseline and sequential results for clinical measures

                                                                Baseline     4 weeks                                                      8 weeks                                                      12 weeks                                                     24 weeks
  ------------------------------------------------------------- ------------ ------------------------------------------------------------ ------------------------------------------------------------ ------------------------------------------------------------ ------------------------------------------------------------
  N (%)                                                                                                                                                                                                                                                             
   Continuing patients                                          30 (100.0)   25 (83.3)                                                    20 (66.7)                                                    19 (63.3)                                                    17 (56.7)
   Responders[\#](#tfn3-ndt-11-3031){ref-type="table-fn"}       0 (0.0)      12 (40.0)                                                    13 (43.3)                                                    12 (40.0)                                                    9 (30.0)
   Remitters[\$](#tfn4-ndt-11-3031){ref-type="table-fn"}        0 (0.0)      6 (20.0)                                                     8 (26.7)                                                     10 (33.3)                                                    7 (23.3)
  Measures                                                                                                                                                                                                                                                          
  Estimate[\#\#](#tfn5-ndt-11-3031){ref-type="table-fn"} (SE)                                                                                                                                                                                                       
  Difference (95% CI)                                                                                                                                                                                                                                               
   HDRS                                                         19.2 (1.2)   12.5 (1.2)[\*\*\*](#tfn8-ndt-11-3031){ref-type="table-fn"}   10.4 (1.3)[\*\*\*](#tfn8-ndt-11-3031){ref-type="table-fn"}   9.1 (1.3)[\*\*\*](#tfn8-ndt-11-3031){ref-type="table-fn"}    8.9 (1.4)[\*\*\*](#tfn8-ndt-11-3031){ref-type="table-fn"}
                                                                             6.7 (3.4, 10.1)                                              8.8 (5.3, 12.4)                                              10.1 (6.4, 13.8)                                             10.3 (6.4, 14.1)
   MADRS                                                        24.7 (1.7)   15.4 (1.8)[\*\*\*](#tfn8-ndt-11-3031){ref-type="table-fn"}   13.8 (2.0)[\*\*\*](#tfn8-ndt-11-3031){ref-type="table-fn"}   12.6 (2.0)[\*\*\*](#tfn8-ndt-11-3031){ref-type="table-fn"}   10.3 (2.1)[\*\*\*](#tfn8-ndt-11-3031){ref-type="table-fn"}
                                                                             9.3 (4.1, 14.6)                                              10.9 (5.2, 16.5)                                             12.1 (6.3, 17.8)                                             14.4 (8.4, 20.4)
   QIDS-SRJ                                                     12.5 (0.9)   9.1 (1.0)[\*](#tfn6-ndt-11-3031){ref-type="table-fn"}        8.2 (1.1)[\*\*](#tfn7-ndt-11-3031){ref-type="table-fn"}      8.2 (1.1)[\*\*](#tfn7-ndt-11-3031){ref-type="table-fn"}      7.9 (1.2)[\*\*](#tfn7-ndt-11-3031){ref-type="table-fn"}
                                                                             3.5 (0.3, 6.6)                                               4.3 (0.9, 7.7)                                               4.3 (0.9, 7.8)                                               4.6 (0.9, 8.2)
   CGI-S                                                        4.2 (0.2)    3.6 (0.2)                                                    3.0 (0.2)[\*\*](#tfn7-ndt-11-3031){ref-type="table-fn"}      2.7 (0.2)[\*\*\*](#tfn8-ndt-11-3031){ref-type="table-fn"}    2.7 (0.2)[\*\*\*](#tfn8-ndt-11-3031){ref-type="table-fn"}
                                                                             0.6 (0.0, 1.3)                                               1.2 (0.5, 1.9)                                               1.6 (0.8, 2.3)                                               1.6 (0.8, 2.3)
   SASS-J                                                       25.9 (1.4)   28.3 (1.5)                                                   29.7 (1.6)[\*](#tfn6-ndt-11-3031){ref-type="table-fn"}       31.3 (1.6)[\*\*](#tfn7-ndt-11-3031){ref-type="table-fn"}     30.9 (1.7)[\*\*](#tfn7-ndt-11-3031){ref-type="table-fn"}
                                                                             −2.5 (−6.0, 1.1)                                             −3.9 (−7.7, −0.2)                                            −5.4 (−9.3, −1.5)                                            −5.1 (−9.1, −1.0)

**Notes:** Values are according to the estimated marginal means using a linear mixed effects model for repeated measures data.

Responders were those who satisfied the response definition, a ≥50% reduction in the HDRS score from baseline at each assessment point.

Remitters were defined according to an HDRS score ≤7 at each assessment point.

Estimate means estimated marginal means.

*P*\<0.05 (vs baseline scores).

*P*\<0.01 (vs baseline scores).

*P*\<0.001 (vs baseline scores).

**Abbreviations:** HDRS, 17-item Hamilton Depression Rating Scale; MADRS, Montgomery-Asberg Depression Rating Scale; QIDS-SRJ, 16-item Quick Inventory of Depressive Symptomatology-Self-Report -- Japanese version; CGI-S, Clinical Global Impressions-Severity; SASS-J, Social Adaptation Self-evaluation Scale; N, the number of patients; CI, confidence interval; SE, standard error.

###### 

Summary of adverse effects (AEs) in this study (n=30)

  AEs                                    Number (%) of patients with AEs   
  -------------------------------------- --------------------------------- -----------------------------------------
  Any AEs                                16 (53.3)                         
  AEs related to milnacipran treatment   16 (53.3)                         
  Moderate-to-severe AEs                 13 (43.3)                         
   AEs leading to withdrawals            8 (26.7)                          
   AEs not affecting continuations       5 (16.7)                          
                                                                           
  **Specific symptoms of AEs**           **All AE (n=23), n (%)**          **Moderate-to-severe AE (n=18), n (%)**
                                                                           
  Hypertension                           3 (10.0%)                         3 (10.0%)
  Orthostatic hypotension                1 (3.3%)                          1 (3.3%)
  Dysuria                                6 (20.0%)                         5 (16.7%)
  Tachycardia                            4 (13.3%)                         2 (6.7%)
  Severe hand tremor                     1 (3.3%)                          1 (3.3%)
  Hyperhidrosis                          1 (3.3%)                          1 (3.3%)
  Headache                               3 (10.0%)                         2 (6.7%)
  Constipation                           3 (10.0%)                         2 (6.7%)
  Insomnia                               1 (3.3%)                          1 (3.3%)

**Notes:** Moderate-to-severe AEs mean that the patients underwent any medical treatment in response to the AEs or were discontinued in the study due to the AEs.

**Abbreviation:** AEs, adverse effects.

###### 

Molecule levels at baseline among patients with or without moderate-to-severe adverse effects

  Molecule                                                           Patients with moderate-to-severe AEs (n=13)   Patients without moderate-to-severe AEs (n=17)   *Z*      *P*-value
  ------------------------------------------------------------------ --------------------------------------------- ------------------------------------------------ -------- --------------------------------------------------------
  **Median (interquartile range)**                                                                                                                                           
  Serum                                                                                                                                                                      
   IL-6 (pg/mL)                                                      0.86 (0.61--3.27)                             0.53 (0.42--1.03)                                −2.155   **0.031**[\*](#tfn14-ndt-11-3031){ref-type="table-fn"}
   IL-8 (pg/mL)                                                      15.32 (13.22--19.74)                          11.85 (9.16--14.01)                              −2.616   **0.009**[\*](#tfn14-ndt-11-3031){ref-type="table-fn"}
   MIP-1β (pg/mL)                                                    102.67 (54.43--188.35)                        124.46 (81.70--159.70)                           −0.021   0.983
   BDNF (ng/mL)                                                      30.70 (28.05--35.90)                          33.30 (25.25--35.73)                             −0.110   0.913
  Plasma                                                                                                                                                                     
   5-HIAA (ng/mL)                                                    4.50 (3.65--6.15)                             4.40 (3.10--5.55)                                −0.838   0.402
   HVA (ng/mL)                                                       9.80 (7.30--15.95)                            8.80 (7.15--10.25)                               −1.026   0.305
   MHPG (ng/mL)                                                      3.90 (3.15--5.55)                             3.60 (2.85--4.25)                                −1.446   0.148
  Whole blood                                                                                                                                                                
   Serotonin (ng/mL)                                                 9.00 (5.50--14.00)                            3.00 (2.00--7.00)                                −2.572   **0.010**[\*](#tfn14-ndt-11-3031){ref-type="table-fn"}
   Platelet (10^9^/L)                                                250.00 (229.50--276.50)                       229.00 (189.00--279.50)                          −1.256   0.209
   Platelet serotonin[\#](#tfn13-ndt-11-3031){ref-type="table-fn"}   4.02 (2.08--6.66)                             1.61 (0.89--3.21)                                −2.448   **0.014**[\*](#tfn14-ndt-11-3031){ref-type="table-fn"}

**Notes:** Moderate-to-severe AEs mean that the patients underwent medical treatment in response to their AEs, or discontinued treatment due to their AEs.

Platelet serotonin means that whole blood serotonin (ng/mL) was divided by platelet level (10^11^/L). Differences between the two groups were analyzed using a two-tailed Mann-- Whitney *U*-test.

The *P*-values in boldface are statistically significant at *P*\<0.05.

**Abbreviations:** IL-6, interleukin-6; IL-8, interleukin-8; MIP-1β, monocyte inflammatory protein-1β; BDNF, brain-derived neurotrophic factor; 5-HIAA, 5-hydroxyindoleacetic acid; HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; AEs, adverse effects.
